Metabolic Consequences of Moderate Weight Gain - Role of Dietary Fat Composition (LIPOGAIN)

Conditions

Healthy

Keywords

Liver fat, Polyunsaturated fatty acids (PUFA), Saturated fatty acids (SFA), Weight gain, Overfeed, Dietary fatty acids, Palm oil, Sunflower oil

Brief summary

The purpose of this study is to investigate the metabolic consequences of a moderate weight gain and if the type of dietary fat (saturated versus polyunsaturated) can modify the effects in young healthy adults. Hypothesis: the type of dietary fat can modify the effects of weight gain.

Detailed description

Specific goals: * Investigate if dietary fat composition influences liver fat accumulation and metabolic risk factors in response to moderate weight gain * Investigate if polyunsaturated fat (PUFA) in the diet could counteract any unfavorable metabolic changes that are expected to accompany moderate weight gain * Investigate effects of weight gain and dietary fat composition on markers of vascular health

Fredrik Rosqvist, Marju Orho‐Melander, Joel Kullberg, David Iggman, Hans-Erik Johansson et al. (8 authors)

Frontiers in Nutrition2020-12-034 citations

10.3389/fnut.2020.606004

Impact of polyunsaturated and saturated fat overfeeding on the DNA-methylation pattern in human adipose tissue: a randomized controlled trial.

Perfilyev A, Dahlman I, Gillberg L, Rosqvist F, Iggman D, Volkov P, Nilsson E, Risérus U, Ling C.

2017-03-08119 citations

10.3945/ajcn.116.143164

Role of Dietary Fats in Modulating Cardiometabolic Risk During Moderate Weight Gain: A Randomized Double‐Blind Overfeeding Trial (LIPOGAIN Study)

David Iggman, Fredrik Rosqvist, Anders Larsson, Johan Ärnlöv, Lena Beckman et al. (7 authors)

Journal of the American Heart Association2014-09-1645 citations

10.1161/jaha.114.001095

Interventions

OTHERPolyunsaturated fatty acid group

Addition of polyunsaturated fatty acids to the diet in the form of pastries

OTHERSaturated fatty acid group

Addition of saturated fatty acids to the diet in the form of pastries

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 38 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy, * Body Mass Index 18-27

Exclusion criteria

* Liver disease, * Coronary heart disease, * Diabetes mellitus, * Malignant diseases, * Alcohol or drug abuse, * Magnetic Resonance-incompatibility, * Abnormal clinical chemistry, * Use of drugs that significantly effects energy metabolism, * Heavy exercise, * Pregnancy or lactation, * Allergy of gluten, egg or milk protein

Design outcomes

Primary

Measure	Time frame
Hepatic steatosis by magnetic resonance tomography (MRT)	6 weeks

Secondary

Measure	Time frame
low density lipoprotein (LDL)	6 weeks
Insulin	6 weeks
Glucose	6 weeks
Triglycerides	6 weeks
Cholesterol	6 weeks
Apolipoprotein B (ApoB)	6 weeks
Apolipoprotein A1 (ApoA1)	6 weeks
Aspartate aminotransferase (ASAT)	6 weeks
Alanine aminotransferase (ALAT)	6 weeks
high density lipoprotein (HDL)	6 weeks
Homeostasis model of assessment insulin resistance (HOMA-IR)	6 weeks
C-reactive protein (CRP)	6 weeks
Proinsulin	6 weeks
Endostatin	6 weeks
Pentraxin-3 (PTX-3)	6 weeks
Endothelin-1 (ET-1)	6 weeks
E-selectin	6 weeks
Cathepsin-S	6 weeks
Cystatin C	6 weeks
Gamma glutamyl transpeptidase (GGT)	6 weeks

Countries

Sweden

Outcome results

None listed